Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorZhongshan People's Hospital, Guangdong, China

About this trial

Based on the preliminary retrospective validation of the efficacy of five HCC screening strategies(including conventional AFP combined with ultrasound-based general screening strategy, REACH-B, AGED, aMAPand aMAP 3.0 risk score) in Xiaolan Town, a head-to-head comparison for HCC screening is conducted in Zhongshan City, Guangdong Province. The study is a prospective, single-center, head-to-head trial aiming to enroll 4,500 HBsAg-positive individuals. It adopts a two-phase design of "HBV screening first, followed by HCC surveillance":Phase I: Recruitment of age-eligible populations at study sites for HBsAg screening to establish a high-risk cohort positive for hepatitis B surface antigen.Phase II: Implementation of uniform HCC surveillance (AFP combined with liver ultrasound every six months) for HBsAg-positive individuals, with concurrent application of different risk stratification models to evaluate risk levels and screening efficacy for each participant during follow-up.Furthurmore, based on baseline biological information and follow-up data, the study also aims to explore the development of a more effective risk prediction model for HCC.

Eligibility criteria

Qualifiers

Voluntarily sign the informed consent form.

Household registration in Zhongshan City, Guangdong Province.

Aged 35 and above.

Positive screening result for Hepatitis B surface antigen (HBsAg).

Disqualifiers

Previous history of liver cancer or liver transplantation.

Pregnant women.

Severe comorbidities (e.g., end-stage cardiopulmonary diseases, advanced malignancies).

Individuals lacking legal capacity or unable to provide informed consent.

Trial design

Treatments tested in this trial

  • Quantitative HBeAg Testing
  • Measurement Indicators Required for Risk Scoring in HCC Screening Strategies
  • Follow-Up Monitoring Parameters

Treatment groups

4,500 Participants
are divided into 1 treatment group